GlassScriptPhysician profile
Jennifer Borson
NPI 1740542141
$1,854.47
in general payments reported to CMS, 2019-2025
33 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $195 · 2021: $87.14 · 2022: $393 · 2023: $415 · 2024: $362 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $902.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $510.95 | 2019-2025 | Lo Loestrin Fe, Orilissa |
| Gynesonics, INC. | $148.53 | 2023-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Astellas Pharma US INC | $131.81 | 2023-2024 | Veozah |
| Hologic Sales and Service, LLC | $113.53 | 2019-2024 | Acessa Provu System, Aptima |
| Sage Therapeutics, LLC | $87.00 | 2024-2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $76.05 | 2019-2024 | Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $70.87 | 2019-2024 | |
| Allergan, INC. | $66.27 | 2019-2020 | |
| Agile Therapeutics, INC. | $65.19 | 2022 | |
| Organon LLC | $57.53 | 2023-2025 | Nexplanon |
| Amag Pharmaceuticals, INC. | $50.51 | 2019-2022 | |
| Coopersurgical, INC. | $47.04 | 2022-2024 | Paragard T 380a |
| Myovant Sciences INC. | $46.04 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $39.66 | 2022-2024 | |
| Pfizer INC. | $34.85 | 2022-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $31.69 | 2019-2022 | |
| Exact Sciences Corporation | $29.51 | 2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $29.09 | 2023 | Myfembree |
| Therapeuticsmd, INC. | $24.93 | 2019-2020 | |
| Smith+Nephew, INC. | $20.59 | 2022 | |
| Channel Medsystems, INC. | $18.79 | 2023 | |
| Minerva Surgical, INC | $17.32 | 2023 | |
| Evofem Biosciences, INC. | $17.14 | 2022 | |
| Supernus Pharmaceuticals, INC. | $15.88 | 2025 | Qelbree |
| Shire North American Group INC | $14.93 | 2019 | |
| Exeltis, USA INC. | $13.75 | 2020 | |
| Mycovia Pharmaceuticals, INC. | $13.71 | 2023 | Vivjoa |
| Avion Pharmaceuticals | $13.69 | 2020 | |
| Mylan Pharmaceuticals INC. | $12.58 | 2022 | |
| Scynexis, INC. | $12.03 | 2022 | |
| Lupin INC. | $12.03 | 2019 | |
| Vertical Pharmaceuticals, LLC | $10.98 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Borson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.